Latest Investor Engagement News

Javelin Minerals has initiated a significant capital consolidation, reducing its share count by a factor of 31, and is introducing a facility to help small shareholders sell untradeable parcels post-consolidation.

ARC Funds Limited has strategically acquired $2.15 million face value of convertible notes in ausbiz TV at just 20% of their value, issuing 4.47 million new shares as consideration. This move aligns with ARC’s growth strategy to diversify income streams and deepen its investment platform.

Complii FinTech Solutions reported a 4.9% year-on-year increase in annual recurring revenue, progressed a major CRM system upgrade, and secured a $1.217 million R&D rebate in Q1 FY26, while managing cash flow pressures.

Aureka Limited reports significant drilling successes at its Victorian gold projects, confirming resource extensions and high-grade intercepts, while initiating a strategic review of its Tandarra joint venture.

Cynata Therapeutics is on track to deliver key clinical trial results in mid-2026 while maintaining a solid cash runway supported by an imminent R&D tax rebate and equity facility.

Litchfield Minerals has identified multiple high-priority conductor targets at its Oonagalabi Project and confirmed significant manganese mineralisation at Lucy Creek, backed by strong funding to advance drilling.

Critica Limited has marked a significant milestone in its Jupiter rare earths project, commissioning a pilot plant and producing its first high-grade mixed rare earth oxide product, underscoring its path from resource to revenue.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

Strickland Metals delivers robust drilling results at its Serbian Rogozna Project, revealing new high-grade copper-gold zones and expanding gold mineralisation footprints, while completing the sale of its Yandal Project to Gateway Mining.

I Synergy Group Limited reported a mixed quarterly cash flow for Q3 2025, highlighting ongoing operational cash outflows but securing financing to extend its runway to just under two quarters.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

TZ Limited reports steady sales growth and new Microsoft contracts in Q1 FY2026, reaffirming its $17–21 million revenue guidance amid improving market conditions.